Clinical Trials · NCT06531499
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
- Phase
- Phase 1
- Recruitment status
- Recruiting
- Sponsor
- Novartis Pharmaceuticals
- Enrollment
- 106
- Start date
- Nov 2024
- Locations
- 21 sites, 6 countries
- Primary endpoint
- Time activity curves (TACs) and absorbed radiation dose of AAA617 in organs